FDA Restricts Use Of Extended-Release Opioids, Requires Post-Marketing Studies

FDA Restricts Use Of Extended-Release Opioids, Requires Post-Marketing Studies

SILVER SPRING, Md. - The Food and Drug Administration on Sept. 10 placed restrictions on the use of extended-release and long-acting (ER/LA) opioid analgesics for pain and will require manufacturers to conduct post-marketing studies and clinical trials to assess the risks of misuse, abuse, diminishing pain relief, addiction, overdose and death.

Find full version on lexis Advance®
Access this news story on lexis.com®